Back to Search
Start Over
Endomyocardial Biopsy: The Forgotten Piece in the Arrhythmogenic Cardiomyopathy Puzzle
- Source :
- Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 19 (2021)
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- Background Endomyocardial biopsy (EMB) is part of 2010 Task Force Criteria (TFC) for arrhythmogenic right ventricular cardiomyopathy (ARVC). However, its usage has been curtailed because of its low presumed diagnostic yield, and it is now a poorly used tool. This study aims to analyze the contribution of EMB to the final diagnosis of ARVC. Methods and Results We included 104 consecutive patients evaluated for a suspicion of ARVC, who were referred for EMB. Patients with suspected left dominant pattern were excluded from the primary analysis. Subjects were initially stratified according to TFC without considering EMB. After EMB, patients were reclassified accordingly, and the reclassification rate was calculated. EMB yielded a diagnostic finding in 92 patients (85.5%). After including EMB evaluation, 20 (43%) more patients “at risk” received a definite diagnosis of ARVC. Overall, 59 patients received a definite diagnosis of ARVC, 34% only after EMB. EMB appeared to be the better‐performing exam with respect to the final diagnosis (β, 2.2; area uder the curve, 0.73; P
Details
- Language :
- English
- ISSN :
- 20479980
- Volume :
- 10
- Issue :
- 19
- Database :
- Directory of Open Access Journals
- Journal :
- Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.0e39f4590c841d6bbfcfbc5f82583f4
- Document Type :
- article
- Full Text :
- https://doi.org/10.1161/JAHA.121.021370